Literature DB >> 26610676

Prostate Artery Embolization (PAE) in the Management of Refractory Hematuria of Prostatic Origin Secondary to Iatrogenic Urological Trauma: A Safe and Effective Technique.

Isaam Kably1, Keith Pereira2, William Chong3, Shivank Bhatia1.   

Abstract

INTRODUCTION: Incidence of refractory hematuria of prostatic origin (RHPO) is extremely rare, with an iatrogenic etiology even rarer. When conservative methods fail to control bleeding, more invasive surgical methods are needed. In this article we describe our experience with prostatic artery embolization (PAE) as a minimally invasive alternative treatment option in patients with RHPO secondary to iatrogenic urologic trauma. TECHNICAL CONSIDERATIONS: Three patients presented with RHPO. The etiologies were transurethral resection of prostate surgery, Foley catheter removal with a supratherapeutic international normalized ratio and self-traumatic Foley catheter removal respectively. Stepwise management with conservative and medical methods failed to control bleeding. Under local anesthesia and moderate sedation, bilateral PAE was performed via a right common femoral artery access and using cone beam computed tomography. An embolic mixture containing 300-500 um Embosphere® Microspheres (Biosphere Medical, Rockland, MA) was injected under fluoroscopic guidance until stasis was achieved. PAE using the described technique was a technical and clinical success in all three patients. Hematuria resolved within a period of 24 hours. There were no intra- or periprocedural complications.
CONCLUSION: PAE offers a reasonable option in treatment of RHPO, regardless of the cause and may be attempted prior to surgical techniques or sometimes in conjunction. Being minimally invasive and performed under local anesthesia, PAE is especially useful when excessive bleeding prevents adequate visualization of a bleeding source during cystoscopy and in the elderly age group with several comorbidities. An added advantage is the prostatic parenchymal ischemia leading to significant prostate volume reduction and alleviation of the obstructive symptoms.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26610676     DOI: 10.1016/j.urology.2015.10.025

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

Review 1.  Review of Current Literature for Prostatic Artery Embolization.

Authors:  Hyeon Yu; Ari J Isaacson; Charles T Burke
Journal:  Semin Intervent Radiol       Date:  2016-09       Impact factor: 1.513

Review 2.  The application of prostate artery embolization in the management of intractable prostate bleeding.

Authors:  Agata Stężewska; Magdalena Stężewska; Bartosz Żabicki; Maciej Salagierski
Journal:  Cent European J Urol       Date:  2020-09-15

3.  Immediate Transurethral Plasma Kinetic Enucleation of the Prostate Gland for Treatment of Benign Prostatic Hyperplasia-Associated Massive Hemorrhage: A Single-Center Experience.

Authors:  Yu Gan; Liang Deng; Qiangrong He; Chao Li; Leye He; Zhi Long
Journal:  Front Surg       Date:  2022-01-12

4.  Clinical Study on the Treatment of Benign Prostatic Hyperplasia by Embolization of Prostate Artery Based on Embosphere Microspheres and Gelatin Sponge Granules.

Authors:  Jinglei Liu; Dianwei Shi; Liang Li; Liming Cao; Jianyu Liu; Jingliang He; Zhihui Liang
Journal:  J Healthc Eng       Date:  2022-01-25       Impact factor: 2.682

5.  Epirubicin-loaded beads transarterial prostatic arterial chemoembolization is a promising treatment for advanced prostate cancer with lower urinary tract obstruction or hematuria-a case series report.

Authors:  Yuting Guan; Wenhao Wang; Tianhui Zhang; Li'an Liao; Jianping Chen; Zhanshang Zhang; Nanhui Chen; Guobin Zeng
Journal:  Transl Androl Urol       Date:  2022-04

6.  Safety and efficacy of transcatheter arterial embolization for management of refractory hematuria of prostatic origin.

Authors:  Jinlong Zhang; Quanyu Wang; Hongwei Zhao; Bing Yuan; Xuedong Sun; Yang Guan; Zhuting Fang; Maoqiang Wang
Journal:  J Interv Med       Date:  2022-05-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.